191729-02-9

Basic information

• Product Name: 2-Chloro-4-(4-methoxyphenylamino)pyrimidine
• Synonyms: 2-Chloro-4-(4-methoxyphenylamino)pyrimidine;2-Chloro-N-(4-methoxyphenyl)pyrimidin-4-amine
• CAS NO: 191729-02-9
• Molecular Formula: C₁₁H₁₀ClN₃O
• Molecular Weight: 235.67
• Product Categories: pharmacetical
• Mol File: 191729-02-9.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 436.9°C at 760 mmHg
• Flash Point: 218°C
• Appearance: /
• Density: 1.324g/cm³
• Vapor Pressure: 7.8E-08mmHg at 25°C
• Refractive Index: 1.631
• CAS DataBase Reference: 2-Chloro-4-(4-methoxyphenylamino)pyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chloro-4-(4-methoxyphenylamino)pyrimidine(191729-02-9)
• EPA Substance Registry System: 2-Chloro-4-(4-methoxyphenylamino)pyrimidine(191729-02-9)

Safety Data

• Hazardous Substances Data: 191729-02-9(Hazardous Substances Data)

Usage

InChI:InChI=1/C11H10ClN3O/c1-16-9-4-2-8(3-5-9)14-10-6-7-13-11(12)15-10/h2-7H,1H3,(H,13,14,15)

Upstream product

• 3934-20-1 2,6-Dichloropyrimidine 
• 104-94-9 4-methoxy-aniline 

Downstream Products

• 1454695-39-6 {2-[4-(7-chloroquinolin-4-yl)piperazin-1-yl]pyrimidin-4-yl}(4-methoxyphenyl)amine 
• 191728-47-9 N₄-(4-Methoxyphenyl)-N₂-(3,4,5-trimethoxyphenyl)-2,4-pyrimidinediamine 
• 837422-24-9 2-chloro-4-(N-(2,6-dimethylphenoxycarbonyl)-N-(4-methoxyphenyl)amino)pyrimidine 
• 898799-79-6 (S)-3-[4-(4-Methoxy-phenylamino)-pyrimidin-2-ylamino]-2-methyl-butan-2-ol 

Relevant articles and documents

Synthesis of piperazine tethered 4-aminoquinoline-pyrimidine hybrids as potent antimalarial agents

A series of 4-aminoquinoline-pyrimidine hybrids linked through piperazine were synthesized and evaluated for their in vitro antimalarial activity against chloroquine (CQ)-sensitive and chloroquine (CQ)-resistant strains of Plasmodium falciparum and cytoto

Design, synthesis and biological evaluation of pyrimidine-based derivatives as VEGFR-2 tyrosine kinase inhibitors

Vascular endothelial growth factor receptor-2 (VEGFR-2) plays a crucial role in tumor angiogenesis, and inhibition of the VEGFR-2 signaling pathway has already become an attractive approach for cancer therapy. In this study, a novel pyrimidine-based derivative 7j was designed as lead compound, and three series of potent VEGFR-2 inhibitors were synthesized and biologically evaluated against A549 and HepG2 cell lines. Compounds 7d, 9s and 13n exhibited superior inhibitory activities against A549 cell with IC50 ranged from 9.19 to 13.17 μM and HepG2 cell with IC50 ranged from 11.94 to 18.21 μM compared to those of Pazopanib (IC50 = 21.18 and 36.66 μM). In addition, molecular docking study was performed to investigate the binding capacity and binding mode between target compounds and VEGFR-2.

Novel CDK2 inhibitor and application thereof in resisting of breast cancer

The invention relates to a CDK2 inhibitor and application thereof, belonging to the technical field of anti-tumor pharmacy. The invention provides a compound as the CDK2 inhibitor. The compound contains a compound represented by a formula (shown in the de